Eledon Pharmaceuticals
ELDN
11 hedge funds and large institutions have $12.5M invested in Eledon Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 6 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
0.1% more ownership
Funds ownership: 2.31% → 2.41% (+0.1%)
17% less capital invested
Capital invested by funds: $15M → $12.5M (-$2.53M)
27% less funds holding
Funds holding: 15 → 11 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$719K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$52.4K |
| 3 |
Renaissance Technologies
New York
|
+$39.4K |
| 4 |
BlackRock
New York
|
+$1.59K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$53K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$17.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.65K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.66K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $10.3M | – | – | – |
|
|
LSC
2
Lyon Street Capital
Sausalito,
California
| $1.38M | +$719K | +9,519 | +102% |
|
|
3
Renaissance Technologies
New York
| $379K | +$39.4K | +522 | +11% |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $168K | -$6.65K | -88 | -4% |
|
|
DC
5
Derby & Company
Newton,
Massachusetts
| $75K | +$77.3K | +1,024 | New |
|
|
6
BlackRock
New York
| $66K | +$1.59K | +21 | +2% |
|
7
D.E. Shaw & Co
New York
| $61K | – | – | – |
|
|
DS
8
DRW Securities
Chicago,
Illinois
| $51K | +$52.4K | +694 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $15K | +$1.06K | +14 | +7% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $6K | -$17.1K | -227 | -73% |
|
|
MAM
11
Meeder Asset Management
Dublin,
Ohio
| $4K | +$755 | +10 | +20% |
|
|
12
Millennium Management
New York
| – | -$53K | -564 | Closed |
|
|
13
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1.66K | -22 | Closed |
|
|
14
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1.36K | -18 | Closed |
|
ELDN Hedge Fund Activity: Q4 2017 in Review
11 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2017, worth a combined $12.5M — down 17% from $15M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELDN and 2 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Lyon Street Capital, adding an estimated $719K. The largest seller was Millennium Management, exiting entirely with an estimated $53K sold.
- 11 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2017, down from 15 in Q3 2017.
- Funds reported $12.5M of Eledon Pharmaceuticals stock for Q4 2017, down 17% quarter-over-quarter.
- 2 funds opened new Eledon Pharmaceuticals positions in Q4 2017 and 6 closed out, a net change of -4 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2017 was Lyon Street Capital, an estimated $719K added.
- The largest Eledon Pharmaceuticals seller in Q4 2017 was Millennium Management, an estimated $53K sold.
Based on aggregated 13F filings for Q4 2017.